Community-acquired pneumonia and acid-suppressive drugs: Position statement;Déclaration sur les pneumonies extrahospitalières et les antiacides

Canadian Journal of Gastroenterology

Volumn 20, Issue 2, 2006, Pages 119-125

  Barkun, Alan ^a  

^a CAG Clinical Affairs Committee ^*

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR;

BACTERIAL COLONIZATION; CANADA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; FATALITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; INTENSIVE CARE; LONG TERM CARE; META ANALYSIS; NOTE; PEPTIC ULCER; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH PH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE ESOPHAGITIS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 33645313741     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/324976     Document Type: Note

References (26)

1. Okie S. What ails the FDA? N Engl J Med 2005;352:1063-6. (Erratum in 2005;352:2563).
2. Drazen JM. COX-2 inhibitors - a lesson in unexpected problems. N Engl J Med 2005;352:1131-2.
3. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005;352:1133,5.
4. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
5. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112:1798-810.
6. Valenzuela JE, Berlin RG, Snape WJ, et at. US experience with omeprazole in duodenal ulcer. Multicenter double,blind comparative study with ranitidine. The omeprazole DU comparative study group. Dig Dis Sci 1991;36:761-8.
7. Rampal P, Martin C, Marquis P, Ware JE, Bonfils S. A quality of life study in five hundred and cighty,onc duodenal ulcer patients. Maintenance versus intermittent treatment with nizatidine. Scand J Gastroenterol Suppl 1994;206:44-51.
8. Pare P, Armstrong D, Pericak D, Pyzyk M. Pantoptazole rapidly improves bealth-related quality of life in patients with heartburn: A prospective, randomized, double blind comparative study with nizatidine. Clin Gastroenterol 2003;37:132-8.
9. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004;4:CD003840.
10. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenat ulcers. Cochrane Database Syst Rev 2002;4:CDO02296.
11. Leontiadis GI, McIntyre L, Sharma VK, Howden CW Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004;3:CDO02094.
12. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004;99:1238-46.
13. Lame L, Alnen D, McClain C, Solcia E, Walsh JH. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68.
14. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000;4:50-4.
15. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998;338:791-7.
16. Mallow S, Rebuck JA, Oster T, Ahern J, Healey MA, Rogers FB. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? Curr Surg 2004;61:452-8.
17. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastrooesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
18. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-35.
19. Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9.
20. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo,controlted study of efficacy and safety. Am J Gastroenterol 2001;96:27-34. (Erratum in 2001;96:942).
21. Richter JE, Bochenek W Oral pantoprazole for eroxive esophagitis: A placebo,controlled, randomized clinical trial. Am J Gastroenterol 2000;95:3071-80.
22. Valenzuela JE, Kogug DG, McCullough AJ, et al. Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: A multicenter, randomized, doubte,blind study. Am J Gastroenterol 1996;91:2516-22.
23. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The US multicenter study. Gastroenterology 1992; 102:109-18.
24. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003;18:847-51.
25. Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am J Med 2003;115:65S-71S.
26. Canadian Association of Gastroenterology, Clinical Affairs. Clostridium difficile-associated diarrhea (CDAD) and proton pump inhibitor therapy: CAG Position Statement. Can J Gastroenterol 2005;19:373-5.